Immunotherapy

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

By Wayne Kuznar

Immunotherapy, NCCN Guideline Updates, National Comprehensive Cancer Network (NCCN)

May 2018, Vol 8, No 5

Cancer Vaccine plus Trastuzumab Shows Promise in HER2 Breast Cancer

By Rebecca Bailey

May 2018, Vol 8, No 5

Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC

By Charles Bankhead

May 2018, Vol 8, No 5

Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC

By Charles Bankhead

Immunotherapy, Immunotherapy

May 2018, Vol 8, No 5

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

By Meg Barbor, MPH

Immunotherapy, Survivorship

April 2018, Vol 8, No 4

Because of the novel mechanisms of action of immunotherapies, extended treatment period, and unique toxicities, cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint, suggested Katy K. Tsai, MD, Clinical Instructor, Division of Hematology/Oncology, University of California, San Francisco (UCSF), at the 2018 Cancer Survivorship Symposium. Read More ›

Switching on the Light: A Model Immunotherapy Program for Oncology Practices

By Gail Thompson

February 2018, Vol 8, No 2

Combining Immunotherapy and Radiotherapy Shows Good Synergy

February 2018, Vol 8, No 2

Immunotherapy: Managing Severe Treatment-Related Toxicities

January 2018, Vol 8, No 1

Opdivo First Immunotherapy Approved for Hepatocellular Carcinoma

Immunotherapy, FDA Approvals, News & Updates

December 2017, Vol 7, No 12

When Does Immunotherapy Work Best in Lung Cancer?

By Wayne Kuznar

Immunotherapy, Lung Cancer

September 2017, Vol 7, No 9

Page 4 of 6

1
2
3
4
5
6